These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15604987)

  • 1. Utility of immunohistochemistry in breast cancer practice.
    Umemura S; Osamura RY
    Breast Cancer; 2004; 11(4):334-8. PubMed ID: 15604987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance.
    Lambein K; Van Bockstal M; Vandemaele L; Geenen S; Rottiers I; Nuyts A; Matthys B; Praet M; Denys H; Libbrecht L
    Am J Clin Pathol; 2013 Oct; 140(4):561-6. PubMed ID: 24045554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.
    Vincent-Salomon A; MacGrogan G; Couturier J; Arnould L; Denoux Y; Fiche M; Jacquemier J; Mathieu MC; Penault-Llorca F; Rigaud C; Roger P; Treilleux I; Vilain MO; Mathoulin-Pélissier S; Le Doussal V
    Histopathology; 2003 Apr; 42(4):337-47. PubMed ID: 12653945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reagent-saving immunohistochemistry for HER2 using non-contact alternating current electric field mixing.
    Hoshino I; Imai K; Nanjo H; Nakamura R; Saito Y; Fujishima S; Saito H; Terata K; Wakita A; Sato Y; Motoyama S; Akagami Y; Minamiya Y
    J Clin Pathol; 2019 Jan; 72(1):25-30. PubMed ID: 30228214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A plea for appraisal and appreciation of immunohistochemistry in the assessment of prognostic and predictive markers in invasive breast cancer.
    Van Bockstal M; Floris G; Galant C; Lambein K; Libbrecht L
    Breast; 2018 Feb; 37():52-55. PubMed ID: 29100044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    Reddy JC; Reimann JD; Anderson SM; Klein PM
    Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study.
    Aimi F; Procopio MG; Alvarez Flores MT; Brouland JP; Piazzon N; Brajkovic S; Dupouy DG; Gijs M; de Leval L
    Virchows Arch; 2019 Sep; 475(3):313-323. PubMed ID: 31267199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3,149 Chinese patients.
    Han X; Shi Y; Ma L; Lyu Z; Yang H; Yao J; Li J; Li B; Qin Y
    Chin Med J (Engl); 2014; 127(2):246-53. PubMed ID: 24438611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparison of IHC and FISH Cytogenetic Methods in the Evaluation of HER2 Status in Breast Cancer.
    Wesoła M; Jeleń M
    Adv Clin Exp Med; 2015; 24(5):899-903. PubMed ID: 26768643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.
    Scheel AH; Penault-Llorca F; Hanna W; Baretton G; Middel P; Burchhardt J; Hofmann M; Jasani B; Rüschoff J
    Diagn Pathol; 2018 Mar; 13(1):19. PubMed ID: 29530054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
    Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
    Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.
    Tang P; Tse GM
    Arch Pathol Lab Med; 2016 Aug; 140(8):806-14. PubMed ID: 27472239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Assessment of Immunohistochemistry Laboratory Performance by Measuring Analytic Response Curves and Limits of Detection.
    Sompuram SR; Vani K; Schaedle AK; Balasubramanian A; Bogen SA
    Arch Pathol Lab Med; 2018 Jul; 142(7):851-862. PubMed ID: 29595317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
    Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
    Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].
    Fernö M; Haglund M; Bendahl PO; Olsson H; Rydén L
    Lakartidningen; 2008 Aug 6-19; 105(32-33):2181-4. PubMed ID: 18780693
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoplex LightCycler polymerase chain reaction quantitation of the HER2 gene for quality assurance of HER2/neu testing by immunohistochemistry and fluorescence in situ hybridization.
    Layfield LJ; Willmore-Payne C; Isom G; Holden JA
    Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):562-7. PubMed ID: 18948825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.